Elmiron Contracts

Our Eligibility & Screening Criteria in Elmiron Cases

At Atraxia Media, we are experienced in successfully connecting law firms with Plaintiffs for Elmiron cases. We have a good track record of delivering contracts to our clients based on their criteria. As Elmiron cases are something that we're very familiar with, we can help by implementing the following marketing plan for your law firm:

• Pre-screening. We make it easy for injured patients to share their information with us. Atraxia Media's thorough approach offers access to comprehensive client data as early as the pre-screening process.
• Screening each case. Our internal intake department oversees every potential Plaintiff review, ensuring you're getting precisely the cases you need.
• Following up with people qualified by our intake department. This phase is critical for moving them towards becoming a client.
• Signing the client on your law firm's behalf. Atraxia Media works with consumers as an extension of your law firm.
• Helping your law firm get more clients. Elmiron is not a real high-volume campaign, but even so, we've been very successful in generating five to ten cases a day for firms.
• Running in-house marketing strategies that generate cases. Atraxia Media's involvement ensures that no Elmiron prospects are overlooked.
• Delivering Elmiron potential Plaintiffs' signed cases reviewed exclusively for your law firm.

Elmiron patients who may be eligible to participate in a lawsuit are the individuals who:

• Took Elmiron for at least two years
• Developed maculopathy, a type of retinal impairment
• Developed vision problems while taking Elmiron or within one year of stopping treatment

Atraxia Media's marketing and intake processes are designed to make it easy for you to pursue Elmiron cases while getting you the most contracts for your investment. When you call us, we'll sit down with you and discuss the campaign you want to run, what constitutes a qualified lead, and what volume you need. After that, we'll handle the rest. With our Elmiron campaigns, all your firm has to manage is pulling medical records. It's that easy.

Elmiron Facts & History

According to recent court documents, there are at least 234 claims relating to the use of Elmiron filed in federal and state courts nationwide. The number of Plaintiffs is expected to continue to climb in the future.

The Judicial Panel on Multidistrict Litigation established consolidated pretrial proceedings for the Elmiron litigation in December 2020. It centralized the claims before U.S. District Judge Brian R. Martinotti in the District of New Jersey for coordinated discovery and a series of early trials.

There is also a pending Elmiron class-action lawsuit against Teva Pharmaceuticals, Ivax, LLC, Janssen Pharmaceuticals, its parent company Johnson & Johnson, Alza Corporation, and Bayer Healthcare Pharmaceuticals. The class-action lawsuit was filed by a group of Plaintiffs that are asking the court to require the companies to pay for medical monitoring to detect the potential vision side effects of Elmiron that may arise anytime in the future.

ELMIRON (PENTOSAN POLYSULFATE SODIUM) PRODUCTS LIABILITY LITIGATION, MDL NO. 2973

Location:

• District of New Jersey

Presiding Judges:

• Hon. Brian R. Martinotti, U.S.D.J.
• Hon. Edward S. Kiel, U.S.M.J.

Plaintiffs:

• Patients diagnosed with pigmentary maculopathy after taking the bladder medication Elmiron.

Defendant:

• Janssen Pharmaceuticals, a division of Johnson & Johnson

Product:

Elmiron (pentosan polysulfate sodium) a prescription medicine used for treating Interstitial Cystitis (IC), also called painful bladder syndrome. This chronic condition causes painful urinary symptoms and usually affects adult women. Between 3-8 million women and 1-4 million men in the U.S. suffer from IC. While there is no cure for IC, various medications, including Elmiron, may ease some symptoms. The FDA approved Elmiron in October 1996. However, several studies show the causal link between Elmiron and progressive retinal damage and central vision impairment. Several dozen eye disorders and vision problems are currently registered in the FDA's FAERS database. In a new case study, the drug's side effects have been linked with the continued deterioration of the eyes for years, even when the drug use was stopped.

Plaintiff Allegations:

The primary claim in Elmiron lawsuits is that the manufacturer Janssen Pharmaceuticals was potentially negligent in adequately warning patients and doctors of known eye-related injury risks. The packaging and warning label did not list maculopathy as a risk before June 16, 2020. Accordingly, consumers were not able to make informed decisions for their healthcare and potentially avoid injuries.

History:

2021:

• May:
• The federal Judge overseeing all Elmiron vision loss lawsuits has issued an order outlining the preliminary strategy for discovery, processes, and bellwether trials, which are set to begin in January 2023.
• April:
• The federal district Judge overseeing all Elmiron lawsuits has approved a procedure for future cases to be filed directly in the federal multidistrict litigation (MDL).
• February:
• According to a product liability lawsuit filed by a Kentucky woman, Johnson & Johnson, its subsidiary Janssen Pharmaceuticals, and Teva Pharmaceuticals, and Alza Corporation, failed to adequately warn users and the medical community about the risk of vision loss and retinal damage caused by Elmiron. After years of taking the bladder medicine Elmiron, the woman had irreversible retina damage, leaving her with persistent eyesight issues.
• According to allegations made in a product liability lawsuit filed by a California woman, she suffered permanent retinal damage and other complications as a result of the controversial bladder pain drug Elmiron. She alleged Johnson & Johnson and its Janssen Pharmaceuticals subsidiary actively concealed information about the drug's serious vision risks.
• Elmiron caused irreversible eye damage, according to a Tennessee woman who claims in a recently filed complaint that the bladder drug's side effects caused severely impaired vision and maculopathy. Teva Pharmaceuticals, Janssen Pharmaceuticals, and its parent firm, Johnson & Johnson, and Alza Corporation were named Defendants in the suit filed in the United States District Court for the District of New Jersey.
• January:
• According to a product liability lawsuit filed against Johnson & Johnson and its Janssen Pharmaceuticals subsidiary, Elmiron reportedly caused permanent eyesight loss and macular degeneration in a Kentucky woman. The case was filed in the United States District Court for the Eastern District of Kentucky, with the Plaintiff alleging that the medication makers hid information about the link between Elmiron and vision-related problems from consumers and the medical community for years.
• According to allegations made in a recent lawsuit, Elmiron's side effects left a New York woman with blurred and cloudy vision. The side effects may show that the drug's makers withheld information from users and the medical community about the risk of permanent retinal damage associated with interstitial cystitis treatment.

2020:

• December:
• According to allegations made in a product liability lawsuit filed by an Illinois man, the adverse effects of Elmiron left him with irreversible retinal injury and vision impairment. The medicine was used for more than 15 years to treat interstitial cystitis.
• Elmiron's side effects may have permanently damaged a woman's vision, causing her to suffer retinal pigmentary alterations, according to a product liability lawsuit filed in California. The action was brought alleging that the interstitial cystitis drug's producers failed to appropriately notify consumers and the medical community about the risks to their vision.
• According to claims made in a new lawsuit, Elmiron's side effects led a Texas woman to go blind and suffer issues that were initially misdiagnosed as pigmentary retinary dystrophy. But her condition turned out to be chorioretinal degeneration induced by years of exposure to the unpleasant bladder treatment.
• Certain allegations in an Elmiron class action case ongoing in Pennsylvania, which called for manufacturers to establish a vision monitoring program for past users of the interstitial cystitis medicine across the country, have been struck down by a federal Judge.
• According to a product liability lawsuit, warnings about the risk of Elmiron toxicity on the retina could have prevented many cases of vision loss and maculopathy among people suffering from bladder pain. A lady filed the suit in the United States District Court for the Northern District of Alabama, alleging that she suffered eye impairments due to toxic maculopathy induced by long-term usage of Elmiron for the treatment of interstitial cystitis.
• November:
• According to claims made in a lawsuit filed over the adverse effects of Elmiron, the medication used for long periods caused permanent vision loss and retina damage in an Ohio lady. The lawsuit was filed in the United States District Court for the District of New Jersey, alleging that the bladder drug's manufacturers neglected to notify patients about the danger of poisoned eyesight.
• October:
• After taking Elmiron for almost 16 years, an Indiana lady claimed that the drug's negative effects caused her to develop macular degeneration and major eyesight issues in a newly filed complaint. The case was filed in Pennsylvania, alleging that Janssen Pharmaceuticals, Inc., a Johnson & Johnson subsidiary, failed to sufficiently notify the medical community about the hazardous eyesight risks connected with Elmiron.
• September:
• According to a product liability complaint, Elmiron may have caused permanent maculopathy and vision loss in thousands of interstitial cystitis patients because the drug's producers failed to offer warnings to consumers and the medical community about the medication's hazardous adverse effects on the retina. In a suit filed in Pennsylvania, the Plaintiff claimed that Janssen Pharmaceuticals suppressed from the public, the medical community, and federal authorities information about maculopathy difficulties suffered by long-term users.
• According to a product liability lawsuit, Johnson & Johnson's Janssen Pharmaceuticals subsidiary marketed Elmiron as a safe and effective treatment for interstitial cystitis. However, the drug fails to provide bladder pain relief and may cause permanent vision problems in users. According to the complaint filed in the United States District Court, long-term usage of the medicine caused a woman to develop maculopathy and did little to alleviate her underlying interstitial cystitis (IC) diagnosis in the Southern District of Ohio.
• The Plaintiff and her husband claimed in a lawsuit that tens of thousands of people across the country are in danger of visual difficulties resulting from long-term use of Elmiron and a previous failure to issue proper warnings to users and the medical community.
• August:
• An Alabama lady filed a product liability claim against the makers of Elmiron, alleging that the interstitial cystitis drug's side effects caused her to develop PPS maculopathy and vision loss.
• According to a product liability lawsuit, a lack of adequate warnings and transparency provided by drug makers about Elmiron vision problems has left an Ohio woman with permanent retina damage after using the interstitial cystitis drug for more than two decades.
• According to allegations raised in a product liability lawsuit, drug makers withheld warnings about the risk of vision problems from Elmiron for years, purposefully deceiving users of the interstitial cystitis drug, as well as doctors and federal regulators.
• In five lawsuits filed in North Carolina, New Jersey, Wisconsin, and Pennsylvania, the Plaintiffs alleged long-term Elmiron use caused pigmentary maculopathy, permanent retinal damage, and vision loss. And that the link between Elmiron and vision problems was withheld from the public and the medical community.
• July:
• Five lawsuits were filed in New Jersey, Pennsylvania, Missouri, and Florida alleging that the side effects of Elmiron caused potentially irreversible or permanent vision damage, pigmentary maculopathy, or severe retinal damage.
• June:
• In three lawsuits filed in New Jersey and Pennsylvania, the Plaintiffs alleged they suffered pigmentary maculopathy, severe visual injury, and vision loss caused by Elmiron side effects.
• May:
• A class-action lawsuit was filed in Pennsylvania against Johnson & Johnson and its Janssen subsidiary seeking medical monitoring and vision exams for users.
• In three product liability lawsuits filed in New Jersey, South Carolina, and Pennsylvania, the Plaintiffs alleged the side effects of Elmiron caused retinal damage, maculopathy, blurry vision, or vision loss.
• In a putative mass tort lawsuit filed in Pennsylvania, the Plaintiff alleged Elmiron side effects placed tens of thousands of patients at risk of vision loss.
• March:
• A lawsuit was filed in Connecticut over allegations that drug makers failed to properly warn physicians and the public that Elmiron could cause vision loss and permanent retinal damage.